Endocrinology

Predicting the outcome for newborns with congenital hyperinsulinism

Babies born with congenital hyperinsulinism (CHI) are at risk of suffering from permanent brain damage and life-long disability.

newborn baby feet
Source: Unsplash/Ignacio Campo

Yet some will go on to suffer more severely than others as a result of their disease profile, report the researchers in an article published in Frontiers in Endocrinology. The research team have found that it is possible to predict when and how the disease may affect the child in the long-term. “One of the problems facing clinicians is that it is really difficult to predict which babies will have problems after surgical treatment. Our new data give some important clues that will help clinicians to know how much extra care each baby is likely to need”, explains Dr Karen Cosgrove, a member of the research team from The University of Manchester. Although generally rare, affecting just 1 in 50,000 children in the UK, CHI can be as common as cystic fibrosis (1 in 2,500) in children of European Jewish descent or when born into communities where cousins marry.

Although the impact of these findings is limited to centres with surgical resources, for those centres the data is immediately applicable and translatable clinically

Mark Dunne

Up until now, scientists have understood that there are two main subtypes of the disease - known as diffuse and focal. Diffuse CHI affects the entire pancreas, whilst focal CHI affects just one area of the organ, forming a focal lesion. The team from Manchester now understand that focal CHI can be further categorised into two types- spreading focal lesions and isolated focal lesions. Spreading focal lesions are generally larger and spread outwards into areas of healthy cells. Isolated focal lesions, on the other hand, have a capsule around them which keeps the diseased cells separate from healthy cells.

The research team investigated the cases of 25 infants with focal CHI to see how the two types of lesions influenced their long-term outcomes. They found that babies with spreading focal lesions suffered more severely from the disease and were diagnosed earlier. These infants were more likely to suffer brain damage which permanently affected their development, learning and behaviour. In contrast, in infants with isolated lesions, the disease was diagnosed later and surgery to remove the lesion was less complicated.

These new data help to explain why new-born babies diagnosed with the same disease may go on to have very different outcomes and could influence the way clinicians choose to manage each new case of CHI. “Although the impact of these findings is limited to centres with surgical resources, for those centres the data is immediately applicable and translatable clinically” explains Professor Mark Dunne from The University of Manchester and lead author on the study.


Source: University of Manchester

02.04.2019

More on the subject:
Read all latest stories

Related articles

Photo

Research

First use of vasoprotective antibody in cardiogenic shock

Scientists at the German Centre for Cardiovascular Research (DZHK) have started a study to find out whether a monoclonal antibody restoring vascular integrity is safe and has positive effects on…

Photo

Growing danger

Bowel cancer rising among young adults in Europe

The rate of bowel cancer – also known as colorectal cancer or CRC – is rising among adults aged 20-49 in Europe, suggests new research. Rates rose most steeply among the youngest age group (20-29…

Photo

New study

Ribosome inhibition may hold the key to multi-stage cancer treatment

Nearly 90% of all cancer patient deaths are due to metastasis. A study from Uppsala University shows that a process that allows the cells to metastasise is aided by the synthesis of new ribosomes,…

Related products

Eppendorf - Mastercycler nexus X2

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG
SARSTEDT - Low DNA Binding Micro Tubes

Research use only (RUO)

SARSTEDT - Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH